pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Sanofi ($SNY) · news · pharmadog
← back to Sanofi
News mentioning $SNY
221
stories
19d
Trending: Top biopharma disciplines with jobs live now
biospace
19d
Biopharma hiring hotspots: States, disciplines where demand is highest
biospace
20d
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
21d
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
fiercebiotech
22d
Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
endpoints
22d
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
fiercebiotech
22d
No more Nordisk as Novo goes it alone amid rebranding push
fiercebiotech
23d
J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg
fiercebiotech
25d
Owkin, Servier ink oncology R&D deal to guide discovery and trial design
fiercebiotech
25d
Takeda's R&D chief Andy Plump to retire; Novo Nordisk appoints global research head
endpoints
26d
Takeda’s long-term R&D head announces exit after major pipeline reorganization
biospace
26d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
26d
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
fiercebiotech
26d
August biopharma layoffs impact just over 500, down 90% year over year
biospace
27d
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
27d
Steady stream of crossover rounds stock biotech's IPO pipeline
biospace
28d
Sanofi spells out asthma data, AstraZeneca details COPD win at #ERS26
endpoints
28d
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
stat
28d
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
fiercebiotech
28d
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
29d
Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
fiercebiotech
Sep 3, 26
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
fiercebiotech
Sep 3, 26
US to grant up to $125M for personalized RNA manufacturing innovation
biospace
Sep 2, 26
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
biospace
Sep 2, 26
Teva autoimmune antibody notches ph. 2 win in celiac disease
fiercebiotech
Sep 1, 26
Novartis says MS pill succeeds in two large studies
biopharma dive
Sep 1, 26
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
Aug 31, 26
Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drug
endpoints
Aug 31, 26
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
Aug 31, 26
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
fiercebiotech
← prev
page 2 of 8
next →
